FDA Grants Accelerated Approval to Nuvalent's ALK Lung Cancer Drug
The FDA granted accelerated approval on Nov. 17 to Nuvalent's Nelkarmi (neladalkib) for adults with previously treated, locally advanced or metastatic ALK-positive non-small cell lung cancer. The drug is approved for patients who previously received alectinib as their only ALK inhibitor, or at least two ALK inhibitors plus platinum-based chemotherapy. Approval was based on the phase 1/2 ALKOVE-1 trial, where response rates were 49% among alectinib-pretreated patients and 32% among those with prior multiple ALK inhibitors and chemotherapy. The prescribing information warns of liver, kidney and eye toxicity, elevated creatine phosphokinase, and embryo-fetal toxicity; the recommended dose is 150 mg orally once daily. The application received priority review, breakthrough therapy, and orphan drug designations.